ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action

Core Viewpoint - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from March 10, 2024, to September 29, 2025 [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including being ranked No. 1 for the number of settlements in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake made false and misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].